Studies reporting series of patients and heathy subjects/controls undergoing SCB testing and the proportion with the type 1 Brugada pattern
| Authors . | SCB agent . | . | Clinical settingProportion with a type 1 Brugada pattern . |
|---|---|---|---|
| Papadakis et al.5 | Ajmaline | SADS relatives | 136/670 (20%) |
| Tadros et al.6 | Ajmaline | UCA survivors SADS relatives | 11/54 (20%) 78/583 (13.4%) |
| Hermida et al.7 | Ajmaline | Healthy subjects with suspicious ECGs | 5/55 (9%) |
| Nakazawa et al.8 | Pilsicainide | Mixed cohort with suspicious ECG | 29/55 (53%) |
| Shimeno et al.9 | Pilsicainide | Mixed cohort with suspicious ECG | 35/58 (60%) |
| Ueyama et al.10 | Pilsicainide | Mixed cohort | 55/161 (34%) |
| Hasdemir et al.11 | Ajmaline | Subjects with AVNRT Asymptomatic controls | 26/96 (27%) 3/66 (4.5%) |
| Veltmann et al.12 | Ajmaline | Mixed cohort | 264/677 (39%) |
| Therasse et al.13 | Ajmaline | Mixed cohort | 81/272 (54%) |
| Quenin et al.14 | Ajmaline | Relatives of unexplained sudden deaths without autopsy | 17/94 (18%) |
| Caldwell et al.15 | Ajmaline | SADS relatives | 2/20 (10%) |
| van der Werff et al.16 | Ajmaline | UCA survivors SADS relatives | 3/69 (4%) 7/140 (5%) |
| Wolpert et al.17 | Flecainide | Subjects with prior drug-induced type 1 Brugada pattern with Ajmaline | 15/22 (68%) |
| Shen et al.18 | Flecainide | Suspicious ECG in Singaporean Males | 53/214 (25%) |
| Meregalli et al.19 | Flecainide | Mixed cohort | 64/160 (40%) |
| Cheung et al.a20 | Procainamide Ajmaline | Mixed cohort | 4/94 (4%) 86/331 (26%) |
| Somani et al.a21 | Procainamide | UCA survivors and SADS relatives | 12/174 (7%) |
| Ensam et al.a4 | Ajmaline Procainamide | UCA survivors | 11/51 (22%) 10/70 (14%) |
| Ensam et al.22 | Ajmaline | Healthy subjects | 3/100 (3%) |
| Peters et al.23 | Ajmaline | Patients with ARVC | 9/55 (16%) |
| Maury et al.24 | Ajmaline Flecainide | Patients with myotonic dystrophy and baseline ECG abnormalities | 8/44 (18%) |
| Authors . | SCB agent . | . | Clinical settingProportion with a type 1 Brugada pattern . |
|---|---|---|---|
| Papadakis et al.5 | Ajmaline | SADS relatives | 136/670 (20%) |
| Tadros et al.6 | Ajmaline | UCA survivors SADS relatives | 11/54 (20%) 78/583 (13.4%) |
| Hermida et al.7 | Ajmaline | Healthy subjects with suspicious ECGs | 5/55 (9%) |
| Nakazawa et al.8 | Pilsicainide | Mixed cohort with suspicious ECG | 29/55 (53%) |
| Shimeno et al.9 | Pilsicainide | Mixed cohort with suspicious ECG | 35/58 (60%) |
| Ueyama et al.10 | Pilsicainide | Mixed cohort | 55/161 (34%) |
| Hasdemir et al.11 | Ajmaline | Subjects with AVNRT Asymptomatic controls | 26/96 (27%) 3/66 (4.5%) |
| Veltmann et al.12 | Ajmaline | Mixed cohort | 264/677 (39%) |
| Therasse et al.13 | Ajmaline | Mixed cohort | 81/272 (54%) |
| Quenin et al.14 | Ajmaline | Relatives of unexplained sudden deaths without autopsy | 17/94 (18%) |
| Caldwell et al.15 | Ajmaline | SADS relatives | 2/20 (10%) |
| van der Werff et al.16 | Ajmaline | UCA survivors SADS relatives | 3/69 (4%) 7/140 (5%) |
| Wolpert et al.17 | Flecainide | Subjects with prior drug-induced type 1 Brugada pattern with Ajmaline | 15/22 (68%) |
| Shen et al.18 | Flecainide | Suspicious ECG in Singaporean Males | 53/214 (25%) |
| Meregalli et al.19 | Flecainide | Mixed cohort | 64/160 (40%) |
| Cheung et al.a20 | Procainamide Ajmaline | Mixed cohort | 4/94 (4%) 86/331 (26%) |
| Somani et al.a21 | Procainamide | UCA survivors and SADS relatives | 12/174 (7%) |
| Ensam et al.a4 | Ajmaline Procainamide | UCA survivors | 11/51 (22%) 10/70 (14%) |
| Ensam et al.22 | Ajmaline | Healthy subjects | 3/100 (3%) |
| Peters et al.23 | Ajmaline | Patients with ARVC | 9/55 (16%) |
| Maury et al.24 | Ajmaline Flecainide | Patients with myotonic dystrophy and baseline ECG abnormalities | 8/44 (18%) |
AVNRT, atrioventricular nodal re-entrant tachycardia; SADS, sudden arrhythmic death syndrome; SCB, sodium channel blocker; UCA, unexplained cardiac arrest.
aOverlapping cohorts.
Studies reporting series of patients and heathy subjects/controls undergoing SCB testing and the proportion with the type 1 Brugada pattern
| Authors . | SCB agent . | . | Clinical settingProportion with a type 1 Brugada pattern . |
|---|---|---|---|
| Papadakis et al.5 | Ajmaline | SADS relatives | 136/670 (20%) |
| Tadros et al.6 | Ajmaline | UCA survivors SADS relatives | 11/54 (20%) 78/583 (13.4%) |
| Hermida et al.7 | Ajmaline | Healthy subjects with suspicious ECGs | 5/55 (9%) |
| Nakazawa et al.8 | Pilsicainide | Mixed cohort with suspicious ECG | 29/55 (53%) |
| Shimeno et al.9 | Pilsicainide | Mixed cohort with suspicious ECG | 35/58 (60%) |
| Ueyama et al.10 | Pilsicainide | Mixed cohort | 55/161 (34%) |
| Hasdemir et al.11 | Ajmaline | Subjects with AVNRT Asymptomatic controls | 26/96 (27%) 3/66 (4.5%) |
| Veltmann et al.12 | Ajmaline | Mixed cohort | 264/677 (39%) |
| Therasse et al.13 | Ajmaline | Mixed cohort | 81/272 (54%) |
| Quenin et al.14 | Ajmaline | Relatives of unexplained sudden deaths without autopsy | 17/94 (18%) |
| Caldwell et al.15 | Ajmaline | SADS relatives | 2/20 (10%) |
| van der Werff et al.16 | Ajmaline | UCA survivors SADS relatives | 3/69 (4%) 7/140 (5%) |
| Wolpert et al.17 | Flecainide | Subjects with prior drug-induced type 1 Brugada pattern with Ajmaline | 15/22 (68%) |
| Shen et al.18 | Flecainide | Suspicious ECG in Singaporean Males | 53/214 (25%) |
| Meregalli et al.19 | Flecainide | Mixed cohort | 64/160 (40%) |
| Cheung et al.a20 | Procainamide Ajmaline | Mixed cohort | 4/94 (4%) 86/331 (26%) |
| Somani et al.a21 | Procainamide | UCA survivors and SADS relatives | 12/174 (7%) |
| Ensam et al.a4 | Ajmaline Procainamide | UCA survivors | 11/51 (22%) 10/70 (14%) |
| Ensam et al.22 | Ajmaline | Healthy subjects | 3/100 (3%) |
| Peters et al.23 | Ajmaline | Patients with ARVC | 9/55 (16%) |
| Maury et al.24 | Ajmaline Flecainide | Patients with myotonic dystrophy and baseline ECG abnormalities | 8/44 (18%) |
| Authors . | SCB agent . | . | Clinical settingProportion with a type 1 Brugada pattern . |
|---|---|---|---|
| Papadakis et al.5 | Ajmaline | SADS relatives | 136/670 (20%) |
| Tadros et al.6 | Ajmaline | UCA survivors SADS relatives | 11/54 (20%) 78/583 (13.4%) |
| Hermida et al.7 | Ajmaline | Healthy subjects with suspicious ECGs | 5/55 (9%) |
| Nakazawa et al.8 | Pilsicainide | Mixed cohort with suspicious ECG | 29/55 (53%) |
| Shimeno et al.9 | Pilsicainide | Mixed cohort with suspicious ECG | 35/58 (60%) |
| Ueyama et al.10 | Pilsicainide | Mixed cohort | 55/161 (34%) |
| Hasdemir et al.11 | Ajmaline | Subjects with AVNRT Asymptomatic controls | 26/96 (27%) 3/66 (4.5%) |
| Veltmann et al.12 | Ajmaline | Mixed cohort | 264/677 (39%) |
| Therasse et al.13 | Ajmaline | Mixed cohort | 81/272 (54%) |
| Quenin et al.14 | Ajmaline | Relatives of unexplained sudden deaths without autopsy | 17/94 (18%) |
| Caldwell et al.15 | Ajmaline | SADS relatives | 2/20 (10%) |
| van der Werff et al.16 | Ajmaline | UCA survivors SADS relatives | 3/69 (4%) 7/140 (5%) |
| Wolpert et al.17 | Flecainide | Subjects with prior drug-induced type 1 Brugada pattern with Ajmaline | 15/22 (68%) |
| Shen et al.18 | Flecainide | Suspicious ECG in Singaporean Males | 53/214 (25%) |
| Meregalli et al.19 | Flecainide | Mixed cohort | 64/160 (40%) |
| Cheung et al.a20 | Procainamide Ajmaline | Mixed cohort | 4/94 (4%) 86/331 (26%) |
| Somani et al.a21 | Procainamide | UCA survivors and SADS relatives | 12/174 (7%) |
| Ensam et al.a4 | Ajmaline Procainamide | UCA survivors | 11/51 (22%) 10/70 (14%) |
| Ensam et al.22 | Ajmaline | Healthy subjects | 3/100 (3%) |
| Peters et al.23 | Ajmaline | Patients with ARVC | 9/55 (16%) |
| Maury et al.24 | Ajmaline Flecainide | Patients with myotonic dystrophy and baseline ECG abnormalities | 8/44 (18%) |
AVNRT, atrioventricular nodal re-entrant tachycardia; SADS, sudden arrhythmic death syndrome; SCB, sodium channel blocker; UCA, unexplained cardiac arrest.
aOverlapping cohorts.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
